The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Abstract
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Secondary objectives were to determine biological response rate, time to tumor progression, duration of objective response, health-related quality of life, and safety of Palladia. Experimental Design: Dogs were randomized to receive oral Palladia 3.25 mg/kg or placebo every other day for 6 weeks in the blinded phase. Thereafter, eligible dogs received open-label Palladia. Results: The blinded phase ORR in Palladia-treated dogs (n = 86) was 37.2% (7 complete response, 25 partial response) versus 7.9% (5 partial response) in placebo-treated dogs (n = 63; P = 0.0004). Of 58 dogs that received Palladia following placebo-escape, 41.4% (8 complete response, 16 partial response) experienced objective response. The ORR for all 145 dogs receiving Palladia was 42.8% (21 complete response, 41 partial response); among the 62 responders, the median duration of objective response and time to tumor progression was 12.0 weeks and 18.1 weeks, respectively. Palladia-treated responders scored higher on health-related quality of life versus Palladia-treated nonresponders (P = 0.030). There was no significant difference in the number of dogs with grade 3/4 (of 4) adverse events; adverse events were generally manageable with dose modification and/or supportive care. Conclusions: Palladia has biological activity against canine MCTs and can be administered on a continuous schedule without need for routine planned treatment breaks. This clinical trial further shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs
Patnaik, A. K., Ehler, W. J., & MacEwen, E. G. (1984) · Veterinary Pathology · doi:10.1177/030098588402100503 · Cited by 843
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 816
Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Schnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., & Schoch, C. (2006) · Blood · doi:10.1182/blood-2005-04-1466 · Cited by 380
London, C. A., Hannah, A. L., Zadovoskaya, R., Chien, M. B., Kollias-Baker, C., Rosenberg, M. P., Downing, S., Post, G. S., Boucher, J. F., Shenoy, N. R., et al. (2003) · PubMed · Cited by 280
Self-citationc‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia
Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I., & Reilly, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01449.x · Cited by 262
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit
London, C. A., Galli, S. J., Yuuki, T., Hu, Z.-Q., Helfand, S. C., & Geissler, E. N. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00075-7 · Cited by 249
Self-citationWebster, J. D., Yuzbasiyan-Gurkan, V., Miller, R. A., Kaneene, J. B., & Kiupel, M. (2007) · Veterinary Pathology · doi:10.1354/vp.44-3-298 · Cited by 222
Recent advances in the understanding of mastocytosis: the role of KIT mutations*
Orfao, A., Garcia‐Montero, A. C., Sanchez, L., & Escribano, L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06619.x · Cited by 211
Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors
Letard, S., Yang, Y., Hanssens, K., Palmérini, F., Leventhal, P. S., Guéry, S., Moussy, A., Kinet, J.-P., Hermine, O., & Dubreuil, P. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0067 · Cited by 185
Cited by
Oxindole: A chemical prism carrying plethora of therapeutic benefits
Kaur, M., Singh, M., Chadha, N., & Silakari, O. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.011 · Cited by 349
European consensus document on mast cell tumours in dogs and cats
Blackwood, L., Murphy, S., Buracco, P., De Vos, J. P., De Fornel‐Thibaud, P., Hirschberger, J., Kessler, M., Pastor, J., Ponce, F., Savary-Bataille, K., et al. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00341.x · Cited by 268
Gardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
Self-citationRegan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
A structural analysis of the FDA green book-approved veterinary drugs and roles in human medicine
Scott, K. A., Qureshi, M. H., Cox, P. B., Marshall, C. M., Bellaire, B. C., Wilcox, M., Stuart, B. A. R., & Njardarson, J. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01502 · Cited by 56
Metadata
- Authors
- London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N., & Michels, G. M.
- Venue
- Clinical Cancer Research
- Published
- 2009-06-01
- Volume
- 15
- Issue
- 11
- Pages
- 3856-3865
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149908540
- Cited by
- 424
- References
- 30
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1860
- The paper
- London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N., & Michels, G. M. (2009). Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.